Compare 10X Genomics Inc (TXG) vs United States Natural Gas Fund (UNG) Price & Performance

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.

UNG, the United States Natural Gas Fund, trades at $10.23, up 0.89% on the day, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The fund tracks natural gas futures, with recent news highlighting steady prices amid weather-driven demand shifts and geopolitical tensions affecting commodity markets. Key support and resistance cluster around $10, indicating a critical price zone.

The outlook for UNG hinges on natural gas supply-demand dynamics, with EIA forecasting record highs in 2026, but risks include volatility from weather patterns and Middle East conflicts. Investment appeal lies in exposure to energy themes, though the fund's structure as a futures tracker may lead to divergence from spot prices, as noted in comparative analyses with equity-based ETFs like FCG.